|Bid||3.2600 x 0|
|Ask||3.2800 x 0|
|Day's Range||3.2000 - 3.3300|
|52 Week Range||0.8700 - 4.3500|
|Beta (3Y Monthly)||3.58|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.50|
TORONTO, May 13, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a medical cannabis company with core operations in Latin America, reports that the Company's previously announced agreement for the acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"), is progressing as planned and the Company is in the latter stages of securing local regulatory approvals in Uruguay for the completion of the Acquisition.
Proxy voting deadline is May 29, 2019 at 11 a.m. (Toronto time). Board of Directors recommends that Shareholders vote FOR all resolutions. TORONTO, May 10, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a medical cannabis company with core operations in Latin America, today announced it has commenced the mailing of the management information circular and other related materials (collectively, the "Meeting Materials") to Khiron's shareholders ("Shareholders") in connection with the annual general and special meeting of Shareholders (the "Meeting").
In the news release, Khiron Life Sciences Enters into $25 Million Bought Deal Equity Financing, issued 06-May-2019 by Khiron Life Sciences Corp. over CNW, we are advised by the company that the first paragraph, last sentence, should read "Common Share of $2.90" rather than "Common Share of $3.00" as originally issued inadvertently. TORONTO, May 6, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), a medical cannabis company with core operations in Latin America, announced today that it has entered into an agreement with Canaccord Genuity Corp. and BMO Capital Markets as co-lead underwriters and joint bookrunners, on behalf of a syndicate of underwriters (together, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, 8,621,000 common shares of the Company ("Common Shares"), on a "bought deal" basis pursuant to a short form prospectus offering, subject to all required regulatory approvals, at a price per Common Share of $2.90 (the "Issue Price") for gross proceeds of $25,000,900 (the "Offering").
Panaxia Pharmaceutical Industries Israel and pharmaceutical company Rafa signed a collaboration agreement with PlantEXT Ltd., an Israeli-Canadian medical cannabis company. Under the agreement, the parties will co-develop the next generation of medical cannabis products intended for patients suffering from Inflammatory Bowel Disease, and who are authorized to receive treatment with medical cannabis. Khiron Life Sciences (TSXV: […]The post Cannabis Stock News Daily Roundup May 1 appeared first on Market Exclusive.
Secured approximately $40 million of investment capital for cultivation site construction, product development and distribution Became the first Colombian cannabis company to list on the TSX Venture Exchange ...
Subscribers of the world's largest beauty subscription service will soon be joining the cannabis ...